On Feb. 7 2023, Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a contract manufacturing agreement with Thermo Fisher Scientific to support the manufacturing of Elektrofi’s ultra-high concentration subcutaneous products.
The technology is designed to enable patients to self-inject biologic-based therapies at home instead of a hospital setting. The new collaboration will facilitate the establishment of a platform current good manufacturing practice (CGMP) line and is scheduled to be operational in early 2024. This is intended to support early clinical efforts across a variety of pipeline programs and enable rapid scale-up for late-stage and commercial development.